## Session 1  9:00-12:45

### 9:00 Official opening of the conference  
Dean Gosset

### HCHWA-D  
*Moderators: Mark van Buchem (Leiden, NL)  
& Gaël Nicolas (Rouen, FR)*

#### 9:15 Introductory talk  
Jolanda Blom (HCHWA-D Patient Organization)

#### 9:25 Imaging markers of presymptomatic HCHWA-D patients.  
Sanneke van Rooden (Leiden, NL)

#### 9:55 Anti-sense oligonucleotide treatment in HCHWA-D.  
Willeke van Roon (Leiden, NL)

#### 10:25 Hereditary cerebral amyloid angiopathy (HCAA)-type mutations increase β-amyloid’s binding affinity for fibrinogen, delayed fibrinolysis, and fibrin deposit formation in the brains of HCAA patients  
Hyung Jin Ahn (New-York, USA)

#### 10:35 CO2-challenge measured with dual echo arterial spin labeling as a whole brain biomarker of cerebrovascular reactivity in HCHWA-D  
Sophie Schmid (Leiden, NL)

#### 10:45 Novel CAA-specific compounds for PET imaging: an update on a preclinical study in APP/PS1 mice  
Milos Ikonomovic (Paris, FR)

### 10:55 Coffee Break

### 11:15 PiB-PET imaging in HCHWA-D in Australia and the Netherlands.  
Jasmeer Chhatwal (Boston, MA, USA)

### 11:45 Candidate therapy studies for Icelandic-type hereditary CAA  
Hakon Hakonarson (Philadelphia, PA, USA)

### 12:15 Cerebral amyloid angiopathy influences clinical phenotype in familial Alzheimer’s disease  
Natalie S Ryan (London, UK)

### 12:25 Imaging characteristics of duplication of the app  
Lou Grangeon (Rouen, FR)

### 12:35 Feasibility of an active immunization clinical trial with a vaccine targeting amyloid-β vaccine in patients with HCHWA-D.  
Kawita Kanhai  
*Moderators: Hameed Sohradi (Perth, AU)  
& Marieke Wermer (Leiden, NL)*

### 12:45 Lunch Break
## Session 2  2:00- 5:30pm

### Biomarkers of CAA

**Moderators: Fabrizio Piazza (Milan, IT) & Susanna Schraen (Lille, FR)**

**2:00 MRI Correlates of Autopsy-proven CAA**  
Konstantinos Arfanakis (Chicago, IL, USA)

**2:30 New Insights from PET Molecular Imaging of CAA**  
Anand Viswanathan (Boston, MA, USA)

**3:00 Blood-brain barrier leakage and microvascular lesions in cerebral amyloid angiopathy - A post mortem MRI and histopathology study**  
Whitney M. Freeze (Boston, USA)

**3:10 Evidence for human transmission of amyloid-β cerebral amyloid angiopathy**  
Zane Jaunmuktane (London, UK)

**3:20 Comparing whole-brain susceptibility patterns in patients with Alzheimer’s disease & cerebral amyloid angiopathy: a QSM study.**  
Valentina Perosa (Magdeburg, Germany)

**3:30 Coffee Break**

**4:00 Novel body fluid biomarkers for CAA: discovery and clinical implications**  
Marcel Verbeek (Nijmegen, NL)

**4:30 Biomarkers of Cognitive Dysfunction in CAA**  
Yael Reijmer (Utrecht, NL)

**5:00 Blood Metabolomic Profiling in Cerebral Amyloid Angiopathy, Alzheimer’s Disease, and Controls**  
Shuang Zhao (Alberta, Canada)

**5:10 Cerebellar Hemorrhagic Distribution as a New Imaging Marker for Cerebral Amyloid Angiopathy**  
Hsin-Hsi Tsa (Taipei, Taiwan)

**5:20 Blood begets blood”: Cortical superficial siderosis progression in a prospective cohort of cerebral amyloid angiopathy**  
Thanakit Pongpitakmetha (Boston, USA)

**5:30 End of the day**

**8:00 Gala dinner**
Friday, September 7th, 2018

**Session 3  9:00-12:30**

**CAA Biology and Physiology**

*Moderators: Susanne van Veluw (Boston, USA) & Vincent Berezowski (Lille, FR)*

9:00 Effect of biological variants of ApoJ and ApoA-I in experimental models of cerebral β-amyloidosis
*Mar Hernandez-Guillamon (Barcelona, ES)*

9:30 Vasoactive properties of amyloid β isoforms correlate with their specific expression in CAA
*Lieke Jäkel (Nijmegen, NL)*

10:00 Silent cerebral microbleeds induce long-term cognitive decline in the non-diseased mouse
*Maud Pétrault (Lille, FR)*

10:10 Connexin 43 and Cx43-20kDa isoform lead to vascular injury in cerebral amyloid angiopathy
*Anuska Andjelkovic. (Ann Arbor MI, USA)*

10:20 Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy
*H. Bea Kuiperij (Nijmegen, NL)*

12:00 Reduced vessel reactivity in mice with vascular Aβ deposition is associated with impaired paravascular clearance
*Susanne J. van Veluw (Boston, USA)*

12:20 Cerebrovascular smooth muscle cells as the drivers of perierterial lymphatic drainage of the brain
*Roxana Aldea, (University of Kentucky, USA)*

*Moderators: Roxana O Carare (Southampton, UK) & Régis Bordet (Lille, FR)*

12:30 Lunch break

**Session 4  2:00-3.30pm**

**Clinical Implications and Therapeutic Dilemmas**

*Moderator: Karin Klijn (Nijmegen, NL) and Edip Gurol (Boston, USA)*

2:00 Can we anticoagulate CAA patients in the context of atrial fibrillation?
*Rustam Al-Shahi Salman (Edinburgh, UK)*

2:30 Cognitive impairment in CAA patients: towards a diagnostic and therapeutic approach?
*Jérémie Pariente (Toulouse, FR)*

3:00 A Cohort Study on the Natural History of Cerebral Amyloid Angiopathy-related inflammation: Evaluation of the Long-Term Outcomes of Immunosuppressive Therapy.
*Fabrizio Piazza (Milano, Italy)*

3:10 Serum anti-Aβ antibody signatures in cerebral amyloid angiopathy manifestations
*Yannick Chantran (Paris, FR)*

10:30 Coffee Break
3:20 Cognitive profile of MCI patients with cerebral amyloid angiopathy
An ancillary study of the BALTAZAR cohort
Géraldine Buard (Lille, FR)

15:30 Coffee Break

4:00 Transient focal neurological episodes: how to recognize and how to treat?
Speaker: Eric Smith (Calgary, CA)

4:30 The difficult diagnosis of CAA related inflammation

Part 1: Diagnosis
Speaker: Auriel Eytan (Tel Aviv, Israel)

Part 2: Treatment
Speaker: Sonia Alamowitch (Paris, FR)

5:00 Poster walk
Moderators: Grégory Kuchcinsky (Lille, FR) & Ellis van Etten (Leiden, NL)

5:30 End of the day
Saturday, September 8th 2018

Session 5  9:00-12:30

Emerging Diagnostic Methods for CAA
Moderators: Steve Greenberg (Boston, USA) & Stephanie Bombois (Lille, FR)

9:00 CT-based criteria for CAA
Mark Rodrigues (Edinburgh, UK)

9:30 Guidelines for cortical superficial siderosis detection, rating and classification
Frank Wollenweber (Munich, DE)

10:00 Subarachnoid extension of lobar hemorrhage on MRI in the acute and subacute phase is associated with the presence of criteria of probable cerebral amyloid angiopathy
Dimitri Renard (Nimes, France)

10:10 Blood begets blood”: Cortical superficial siderosis progression in a prospective cohort of cerebral amyloid angiopathy
Thanakit Pongpitakmetha (Boston, USA)

10:20 Cerebellar microbleeds distribution and cerebral amyloid angiopathy: an MRI and pathology-based study
Marco Pasi (Boston, USA)

10:30 Coffee Break

11:00 Incidence of cerebral microbleeds and amyloid burden: the Mayo Clinic Study of Aging
Jonathan Graff-Radford (Mayo Clinic, USA)

11:10 Texture-based Individual-level Classification of Normal-Appearing White Matter and White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Healthy Controls
Klourfeld E (Calgary, Canada)

11:20 Pathologic lesions associated with clinical impairment
Julie Schneider (Chicago, IL, USA)

11:50 Boston Criteria version 2.1
Andreas Charidimou (Boston, MA, USA)

Moderators: David Werring (London, UK) and Sarah Shams (Stockholm, SE)

12:30 Conclusion & iCAA 2020

12:45 End of the conference

This conference is supported by

This meeting is endorsed by the European Stroke Organization. It is open to all who are interested in cerebrovascular diseases. http://www.eso-stroke.org/
Link to the next ESO Conference: http://eso.kenes.com/